Tocagen Inc (TOCA) Receives $22.80 Consensus Price Target from Brokerages
Tocagen Inc (NASDAQ:TOCA) has earned a consensus recommendation of “Buy” from the eight analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $22.80.
TOCA has been the subject of several analyst reports. Zacks Investment Research lowered shares of Tocagen from a “hold” rating to a “sell” rating in a report on Thursday, August 16th. Chardan Capital initiated coverage on shares of Tocagen in a report on Thursday, August 30th. They issued a “buy” rating and a $30.00 target price for the company. ValuEngine raised shares of Tocagen from a “hold” rating to a “buy” rating in a report on Friday, November 2nd. B. Riley increased their price objective on shares of Tocagen from $15.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, September 20th. Finally, BidaskClub lowered shares of Tocagen from a “buy” rating to a “hold” rating in a report on Friday, October 5th.
A number of institutional investors and hedge funds have recently made changes to their positions in TOCA. Raymond James & Associates purchased a new stake in Tocagen during the 2nd quarter valued at approximately $142,000. First Republic Investment Management Inc. purchased a new stake in Tocagen during the 2nd quarter valued at approximately $170,000. Beaumont Financial Partners LLC purchased a new stake in Tocagen during the 3rd quarter valued at approximately $212,000. Citadel Advisors LLC purchased a new stake in Tocagen during the 3rd quarter valued at approximately $251,000. Finally, Granahan Investment Management Inc. MA grew its holdings in Tocagen by 16.0% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 42,438 shares of the company’s stock valued at $396,000 after buying an additional 5,839 shares in the last quarter. 29.68% of the stock is owned by institutional investors and hedge funds.
Tocagen (NASDAQ:TOCA) last released its earnings results on Thursday, November 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.22. The company had revenue of $18.01 million during the quarter, compared to analyst estimates of $2.01 million. Tocagen had a negative net margin of 222.81% and a negative return on equity of 71.61%. On average, analysts predict that Tocagen will post -2.49 EPS for the current year.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Featured Story: Inflation
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.